The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development

Author(s): H. Blasco, S. Mavel, P. Corcia, P.H. Gordon.

Journal Name: Current Medicinal Chemistry

Volume 21 , Issue 31 , 2014

  Journal Home
Translate in Chinese
Submit Manuscript
Submit Proposal

Abstract:

Amyotrophic lateral sclerosis (ALS) is an age-related neurodegenerative disorder that is believed to have complex genetic and environmental influences in the pathogenesis, but etiologies are unidentified for most patients. Until the major causes are better defined, drug development is directed at downstream pathophysiological mechanisms, themselves incompletely understood. For nearly 30 years, glutamate-induced excitotoxicity has lain at the core of theories behind the spiraling events, including mitochondrial dysfunction, oxidative stress, and protein aggregation, that lead to neurodegenerative cell death. One drug, riluzole, which possesses anti-glutamatergic properties, is approved as neuroprotective for ALS. Following the achievement of the riluzole trials, numerous other agents with similar mechanisms have been tested without success. This article provides an overview of excitotoxicity in ALS, focusing on the events that contribute to excess glutamate, how the excess might damage nerve cells, and how this information is being harnessed in the development of potential new neuroprotective agents. The work highlights clinical trials of drugs that have targeted the glutamate system, comments on the potential role of glutamate as a biomarker and concludes with a section on future directions for the field. As research uncovers elusive etiologies and brings clarity to pathophysiological mechanisms, the success of new interventions will increasingly depend on the design of agents that target particular mechanisms for specific individuals. The heady future of personalized drug regimens for ALS rests with medicinal chemists, the scientists whose ideas and work produce these designer drugs.

Keywords: Amyotrophic lateral sclerosis, neurodegeneration, glutamate, pathophysiology, diagnosis, treatment.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 21
ISSUE: 31
Year: 2014
Page: [3551 - 3575]
Pages: 25
DOI: 10.2174/0929867321666140916120118
Price: $58

Article Metrics

PDF: 100